黄玉辉

教授,博士生导师

      

江苏省苏州市工业园区仁爱路199703号楼507

苏州大学唐仲英血液学研究中心

电话:86-512-658808773507

传真:86-512-65880929

Email: huangyh@suda.edu.cn

 

 

 

教育背景:

1992-1996     南京大学                                         生物化学系                             学士

2000-2003     中科院上海生命科学研究院            分子生物学与生物化学专业    硕士

2003-2007     美国范德比尔特大学                     肿瘤生物学专业                      博士

2008-2013     美国哈佛大学医学院麻省总医院     博士后

 

工作经历:

 

19967-20008     丽珠医药集团股份有限公司        工程师

20141-20146     美国美奥医学中心                       助理教授

20147-至今               苏州大学                                     特聘教授

 

研究领域及内容:

 

肿瘤免疫微环境和免疫治疗

肿瘤在我国的发生率和死亡率正逐年上升,而传统的化疗和放疗往往仅能短暂延长病人的寿命。近年来在肿瘤免疫治疗上的进展为治愈恶性肿瘤带来了一丝曙光。目前,肿瘤免疫治疗面临的一大障碍是异常的肿瘤血管和免疫抑制性的肿瘤微环境。它们不仅阻碍抗肿瘤有效成分的输送,而且也抑制了它们的活性和导致了抗药性。我的实验室将致力于研究肿瘤免疫微环境的特性及形成机理,解析肿瘤与免疫系统之间的相互作用机制,并通过融合肿瘤免疫学、肿瘤血管控制、生物靶标和纳米技术等来发展高效特异的肿瘤靶向免疫治疗方略。

 

团队成员:

研究助理:王学祥

博士研究生:曦晨,刘永浩

士研究生:周培,刘小梅,声明,范鹏,蒯佳婕,钱龙,张耐冬

 

代表性成果:

 1.      Zheng X#, Fang Z#, Liu X, Zhou P, Deng S, Wang X, Zhang C, Yin R, Hu H, Chen X, Zhao Y, Lin S, Qin S, Wang X, Kim B, Zhou P, Jiang W, Wu Q, Huang Y*. Increased vessel perfusion predicts the efficacy of immune checkpoint blockade. J. Clin. Invest. 128(5): 2104-2115, 2018.

2.      Huang Y*, Kim BYS, Chan CK, Hahn SM, Weissman IL, Jiang W*. Improving immune-vascular crosstalk for cancer immunotherapy. Nat. Rev. Immunol. 18(3): 195-203, 2018.

3.      Peterson TE#, Kirkpatrick ND#, Huang Y#, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK*. Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 113(16): 4470-5, 2016.

4.     Jiang W#, Huang Y#, An Y, Kim B*. Remodelling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles. ACS Nano 9(9): 8689-96, 2015.

5.       Huang Y, Carbone DP*. Mechanisms of and Strategies for Overcoming Resistance to Anti-vascular Endothelial Growth Factor Therapy in Non-small Cell Lung Cancer. BBA Reviews on Cancer 1855(2):193-201, 2015.

6.       Huang Y, Goel S, Duda DG, Fukumura D, Jain RK*. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73: 2943-8, 2013.

7.       Huang Y, Stylianopoulos T, Duda DG, Fukumura D, Jain RK*. Benefits of vascular normalization are dose and time dependent-letter. Cancer Res 73: 7144-6, 2013.

8.       Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK*, Poznansky MC. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc Natl Acad Sci U S A 109: 17561-6, 2012.

9.       Huang Y, Snuderl M, Jain RK*. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 19: 1-2, 2011.

10.    Huang Y, Lin L, Shanker A, Malhotra A, Yang L, Dikov MM, Carbone DP*. Resuscitating cancer immunosurveillance: selective stimulation of DLL1-Notch signaling in T cells rescues T-cell function and inhibits tumor growth. Cancer Res 71: 6122-31, 2011.

11.    Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, Carbone DP*. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 110: 624-31, 2007.

12.    Snuderl M#, Batista A#, Kirkpatrick ND#, Ruiz de Almodovar C, Riedemann L, Walsh EC, Anolik R, Huang Y, Martin JD, Kamoun W, Knevels E, Schmidt T, Farrar CT, Vakoc BJ, Mohan N, Chung E, Roberge S, Peterson T, Bais C, Zhelyazkova BH, Yip S, Hasselblatt M, Rossig C, Niemeyer E, Ferrara N, Klagsbrun M, Duda DG, Fukumura D, Xu L, Carmeliet P, Jain RK*. Targeting placental growth factor/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152: 1065-76, 2013.

13.    Incio J, Ligibel JA, McManus DT, Suboj P, Pinter M, Jung K, Kawaguchi K, Pinter M, Babykutty S, Chin SM, Vardam TD, Huang Y, Rahbari N, Roberge S, Wang D, Gomes-Santos I, Puchner SB, Schlett CL, Hoffmman U, Ancukiewicz M, Tolaney SM, Krop IE, Duda D, Boucher Y, Fukumura D*, Jain RK*. Obesity promotes resistance to anti-VEGF therapy in breast cancer by upregulating IL-6 and FGF-2, Sci Transl Med 10(432). pii: eaag0945, 2018.

14.    Incio J, Liu H, Suboj P, Chin SM, Chen IX, Pinter M, Ng MR, Nia HT, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari NN, Han X, Chauhan VP, Martin JD, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos TP, Ferrone CR, Soares R, Boucher Y, Fukumura D, Jain RK*. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov 6(8): 852-869, 2016.

15.    Rahbari N, Kedrin D, Incio J, Liu H, Ho W, Nia H, Edrich C, Jung K, Daubriac J, Chen I, Heishi T, Martin J, Huang Y, Maimon N, Reissfelder C, Weitz J, Boucher Y, Clark J, Grodzinsky A, Duda DG, Jain RK, Fukumura D* Anti-VEGF therapy induces ECM remodeling and mechanical barriers to therapy in colorectal cancer liver metastases. Sci Transl Med 8(360): 360ra135, 2016.

16.    Ager E, Kozin S, Kirkpatrick N, Kodack D, Seano G, Huang Y, Goel S, Snuderl M, Askoxylakis V, Dransfield D, Devy L, Muzikansky A, Finkelstein D, Boucher Y, Fukumura D*, and Jain RK*. Blockade of MMP14 activity in murine breast carcinomas: implications for macrophages, vessels, and radiotherapy. J Natl Cancer Inst 107(4), 2015.

17.    Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, Hiddingh L, Roberge S, Koppel C, Lauwers GY, Zhu AX, Jain RK, Duda DG*. Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice. Hepatology 59(4): 1435-47, 2014.

18.    Hiratsuka S#, Duda DG#, Huang Y, Goel S, Sugiyama T, Nagasawa T, Fukumura D, Jain RK*. C-X-C receptor type 4 promotes metastasis by activating p38 mitogen-activated protein kinase in myeloid differentiation antigen (Gr-1)-positive cells. Proc Natl Acad Sci U S A 108: 302-7, 2011.

 

荣誉称号:

2015       江苏省“双创团队”

2015       江苏省“六大高峰人才”

2014       江省第五批“特聘教授”

2014       Distinguished Oral Presentation in Mayo Clinic Young Investigator Research Symposium

2011       Department of Defense (DoD) Postdoctoral Fellowship Award

2010       AACR-Aflac Scholar-in-Training Award

2007       AACR-Merck Scholar-in-Training Award

 

特别感谢天美网络对CBST2015的大力支持,苏州天美网络科技的技术与服务受到业界广泛认可,公司的价值观是专业与可靠,倾心于客户的信息化需求和满意度,具备广泛的客户认同和丰富的行业经验。 同时我们特别感谢专业开发给孩子们的童话工作室你的童话的童话支持,给孩子们的童话呢?给孩子买什么童话故事好?这些问题你可以通过该网站得到答案!点击链接访问你的童话.